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Background   Although indomethacin is effective in pre-
venting heterotopic ossiﬁcation (HO) after primary total 
hip arthroplasty, side effects are frequently observed. In 
the last decade a new class of drugs—the COX-2 selec-
tive nonsteroidal anti-inﬂammatory drugs—has been 
developed. To investigate the effect of these COX-2 
selective NSAIDs on heterotopic ossiﬁcation (HO) after 
primary total hip arthroplasty (THA), we conducted a 
randomized controlled trial using either indomethacin 
or rofecoxib for 7 days.
Methods   186 patients received either indomethacin 
3 times daily, or rofecoxib twice, and 1 placebo, daily for 
7 days. HO was graded according to the 1-year postop-
erative radiographs according to the Brooker classiﬁca-
tion. 
Results   12 of the 186 patients included discontinued 
their medication before the end of the trial due to side 
effects. The remaining 174 patients were included in the 
analysis. In the indomethacin group (n = 89), 77 patients 
(87%) showed no HO, 9 showed HO of grade 1 and 3 
showed HO of grade 2 according to the Brooker classiﬁ-
cation. In the rofecoxib group (n = 85) 73 patients (86%) 
showed no ossiﬁcation, 9 showed grade 1, and 3 showed 
grade 2.
Interpretation   The prophylactic effect of rofecoxib 
for 7 days in preventing heteropic ossiﬁcation after pri-
mary total hip arthroplasty is comparable to the effect 
of indomethacin given for 7 days. These results indicate 
that the development of HO follows a COX-2 pathway. 
■
Although indomethacin is effective in preventing 
heterotopic ossiﬁcation (HO) after primary total 
hip arthroplasty (Knelles et al. 1997, Neal et al. 
2000), side effects are frequently observed. The 
minimum treatment period for NSAIDs appears to 
be 7 days (Neal et al. 2000). Indomethacin used for 
3 (van der Heide et al. 1999) or 4 (Dorn et al. 1998) 
days was found to show inferior results. Traditional 
non-steroidal anti-inﬂammatory drugs inhibit both 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2). In recent years, selective COX-2 inhibi-
tors have been developed; these provide compa-
rable pain reduction but with fewer side effects 
(Bombardier et al. 2000, Feldman and McMahon 
2000, Silverstein et al. 2000) and reduced periop-
erative blood loss (Weber et al. 2003). Due to this 
reduction in side effects, these COX-2 inhibitors 
are attractive options for the prevention of hetero-
topic ossiﬁcation. 
To our knowledge, no data are available in the 
literature concerning whether the reduction of the 
heterotopic ossiﬁcation after total hip arthroplasty 
in humans is a COX-1 or COX-2 effect, or the 
result of a yet unknown pathway. To investigate 
the incidence of heterotopic ossiﬁcation (HO) after 
primary total hip arthroplasty (THA), we con-
ducted a double-blind randomized controlled trial 
for prophylaxis using either indomethacin or rofe-
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Patients and methods
After approval by the local ethics committee, the 
study was initiated in Rijnstate Hospital, Arnhem, 
the Netherlands, which is a teaching hospital. The 
inclusion and exclusion criteria were as follows. 
Inclusion criteria: primary hip arthroplasty, 
spinal or epidural anesthesia, able to sign an 
informed consent form, and age between 18 and 
85 years. Exclusion criteria: previous surgery on 
the same hip joint, inclusion in another study, any 
history of bleeding disorders, any history of gastric 
ulcer, or rheumatoid arthritis.
All patients who were included signed a writ-
ten informed consent. A power analysis was per-
formed to calculate the number of patients needed 
for this study. From this calculation, we intended 
to include 200 patients. However, the inclusion of 
patients for this study was terminated on the day 
Merck withdrew rofecoxib from the market, i.e. 
September 30, 2004 (Couzin, 2004, Dieppe et al. 
2004). At that time, 186 patients had already been 
included (58 males and 116 females). All non-ste-
roidal anti-inﬂammatory drugs were stopped 10 
days before surgery. Patients started their medi-
cation on the morning of surgery and continued 
it until the sixth postoperative day; thus, the trial 
period was 7 days. Each patient who was included 
received a package with 21 capsules, 7 labelled 
“morning”, 7 “afternoon”, and 7 “evening”. The 
medication was repacked in numbered packages, 
and the pharmacologist executed the randomiza-
tion procedure. The packages were used under 
code by both patients and physicians. In the rofe-
coxib group, the patients received 3 capsules a day; 
the morning and evening tablet consisted of 25 mg 
rofecoxib, and the afternoon tablet was a placebo. 
In the indomethacin group, patients received indo-
methacin (50 mg) 3 times a day. No other NSAIDs 
were allowed for two months postoperatively. 
When necessary, patients were allowed to take ace-
tominophen (Paracetamol).
All hips were implanted using the posterolateral 
approach and all patients received 2 g cefazoline i.v. 
before surgery. A suction drain was used, which was 
removed on the ﬁrst or second day postoperatively. 
All patients started weight bearing mobilization on 
the ﬁrst postoperative day. Thrombo-embolic pro-
phylaxis was given in a daily subcutaneous injec-
tion of 0.3 mL nadroparine (Fraxiparine) (2,850 
IE) for 6 weeks. 
All patients were reviewed 1 year postoperatively 
by one investigator (HvdH), and the pelvic radio-
graphs were scored for HO according to Brooker 
et al. (1973). The investigator was blinded as to the 
prophylactic treatment given to the patient. 
We used SPSS software version 11.5 for statisti-
cal analysis. The incidence of HO was estimated 
in both groups. Conﬁdence intervals for these esti-
mates were computed using the normal approxi-
mation to the binomial distribution, as was the con-
ﬁdence interval for their difference.
Results
12 patients (7%) of the 186 patients who were 
included discontinued their medication before the 
end of the trial due to side effects, mainly nausea 
and vomiting (6 in the indomethacin group and 6 in 
the rofecoxib group), and they were excluded from 
further analysis. Of the 174 remaining patients, 
86% of the patients in the rofecoxib-group (95% 
CI 78–93%) showed no signs of HO, as compared 
to 87% (95% CI 79–94%) in the indomethacin 
group (Table). This difference (1%, 95% CI –10 to 
11%) was not signiﬁcant (p = 0.9). 
Discussion
We found no difference between the selective 
COX-2 inhibitor rofecoxib and indomethacin in the 
prevention of heterotopic ossiﬁcation after primary 
THA. Considering the effectiveness of NSAIDs 
(Knelles et al. 1997, Neal et al. 2000) and the fact 
that in our hospitals all patients receive standard 
The distribution of HO between the two treatment 
groups, no difference
Heterotopic ossiﬁcation Indomethacin Rofecoxib
(Brooker grading) (n = 89) (n = 85)
Grade 0 77 (87%) 73 (86%)
Grade 1   9 (10%)   9 (11%)
Grade 2   3 (3%)   3 (3%)
Grade 3   0    0 
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NSAID prophylaxis for HO, from an ethical stand-
point we elected not to use a placebo-controlled 
study design. 
Although indomethacin is a powerful drug for 
prevention of heterotopic ossiﬁcation, the high 
incidence of side effects (Neal et al. 2000) poses a 
clinical problem. Knelles et al. (1997) showed 22% 
side effects which resulted in study withdrawal of 
2%. Cella et al. (1988) found contraindications to 
indomethacin in one-ﬁfth of patients and one-third 
of their patients were withdrawn from the study.
Given the side effects of indomethacin, several 
other NSAIDs have been investigated for their 
prophylactic effect on HO. In recent years, more 
COX-2 selective inhibitors have been developed 
with fewer side effects (Bombardier et al. 2000, 
Feldman and McMahon 2000, Laine 2002, Gajraj 
2003) and the same pain-reducing effects (Degner 
et al. 1998, Dequeker et al. 1998, Hawkey et al. 
1998, Schoenfeld 1999, Feldman and McMahon 
2000). The effect on HO of this newer class of 
NSAIDs is described circumstantially: the effect 
of meloxicam is contrasting; some studies have 
shown the same effect (Legenstein et al. 2003, 
van der Heide et al. 2004), while another showed 
inferior results (Barthel et al. 2002). The effect of 
celecoxib has been described by Romano et al. 
(2004), and is comparable to the effect of indo-
methacin. The latter authors found, however, that 
fewer patients in the celecoxib group had to dis-
continue their medication due to side effects as 
compared to those in the indomethacin group. In 
our study, the proportion of patients who stopped 
their medication before the seventh day was simi-
lar to these results (7%). In our study, it is striking 
that the number of patients who discontinued their 
medication due to side effects was exactly the same 
in both groups. 
To our knowledge, there have been no publica-
tions reporting the effect of rofecoxib on HO after 
primary total hip replacement. The only paper 
adressing the possible effect of rofecoxib on HO 
was the study by Banovac et al. (2004). However, 
these authors described the prophylactic effect on 
HO after spinal cord injury. Although rofecoxib has 
been withdrawn from the market, we consider that 
the current study is still interesting because little 
is known about the effect of the selective COX-
2 inhibitors on the incidence of HO. It is likely 
that the prophylactic effect of rofecoxib is a class 
effect of all COX-2 selective inhibitors, and this 
study gives more information regarding the effect 
of this speciﬁc group. Furthermore, rofecoxib may 
perhaps be re-introduced onto the market for short-
term use. Another important advantage of this new 
class of drugs may be the reduction of perioperative 
blood loss. Kristensen et al. (1990) found increased 
perioperative blood loss after the use of indometh-
acin, due to the reduction in platelet aggregation. 
Weber et al. (2003) found a decrease in peropera-
tive and postoperative blood loss of 15% in the 
meloxicam group relative to the indomethacin 
group. However, serious concerns have been raised 
about the possible deleterious effects of NSAIDs—
and especially the COX-2 selective ones—on bone 
healing and bone ingrowth in implants (Aspenberg 
2002, 2005b, Burd et al. 2003, Dahners and Mullis 
2004). Given the two additional risk factors, i.e. 
the increased cardiovascular risk after long-term 
use and the potential reduction in bone ingrowth 
in uncemented prostheses (Aspenberg 2005a, b), 
this class of drugs must also be fully investigated 
regarding these two issues before widespread use 
can be recommended.
In conclusion, the prophylactic effect of giving 
rofecoxib for seven days for prevention of heteropic 
ossiﬁcation after primary total hip arthroplasty is 
comparable to the effect of indomethacin given for 
7 days.
Note added in proof
A similar study, which we were unaware of, is 
also published in this issue of Acta Orthopaedica 
(Grohs et al. 2007). The other study shows the 
same results as ours, but the incidence of HO was 
much higher in both treatment arms. This can be 
explained by the surgical (anterolateral) approach 
used in their study. A posterolateral approach was 
used in our study. It is known from the literature 
that the incidence of HO using an anterolateral 
approach is higher (Bischoff et al. 1994, Eggli and 
Woo 2001). 
Contributions of authors
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